Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Trastuzumab may cause tufted hair folliculitis as a side effect.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.

Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.